Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Multiple Myeloma 6Lung Neoplasms 6Lymphoma 5Lymphoma, Large-Cell, Anaplastic 3Hematologic Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Relapsed Pediatric Solid Tumor 1Rectal Neoplasms 1Rare Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 2 1

Interventions

vandetanib 1ruxolitinib 1pazopanib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Etoposide 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Relapsed Pediatric Solid Tumor × Crizotinib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡